{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00558:j retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00558%3Aj",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004894,
    "timestamp_received": "2026-04-25T14:14:06.640169+00:00Z",
    "timestamp_returned": "2026-04-25T14:14:06.645063+00:00Z",
    "trace_id": "da3ff868-369d-4b9b-bcdb-552b6692c130"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00558:j",
      "indication": "As monotherapy for the treatment of recurrent, or metastatic cervical cancer with disease progression on or after chemotherapy in adults whose tumours express PD-L1 with a CPS >= 1",
      "initial_approval_date": "2023-04-01",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Cervical cancer",
      "raw_therapeutics": "Pembrolizumab 400mg monotherapy",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00558",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Pembrolizumab 400mg Monotherapy, 2024, version number 12a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6389/558_v12b_Pembrolizumab_400mg_monotherapy.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6389/558_v12b_Pembrolizumab_400mg_monotherapy.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-04-01",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}